Vident Investment Advisory’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Vident Investment Advisory’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-33,486	Closed	-$58.9K	–	1325
2023 Q1	$58.9K	Buy	33,486 +1,243	+4%	+$3.55K	﹤0.01%	1198
2022 Q4	$101K	Buy	32,243 +7,562	+31%	+$29.3K	﹤0.01%	1106
2022 Q3	$121K	Buy	24,681 +2,471	+11%	+$12.7K	﹤0.01%	1050
2022 Q2	$92K	Buy	22,210 +4,396	+25%	+$19K	﹤0.01%	1202
2022 Q1	$103K	Sell	17,814 -3,640	-17%	-$21.6K	﹤0.01%	1229
2021 Q4	$161K	Buy	+21,454	New	+$186K	﹤0.01%	1161
2021 Q3	–	Sell	-18,172	Closed	-$218K	–	1228
2021 Q2	$218K	Buy	+18,172	New	+$206K	0.01%	1020

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vident Investment Advisory's SGMO Position: Q2 2023 in Review

Vident Investment Advisory sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 33,486 shares — an estimated $58.9K sold.

Vident Investment Advisory first reported a position in SGMO in Q2 2021 and held it in 7 quarters. The position peaked at $218K in Q2 2021. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

Vident Investment Advisory reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
Vident Investment Advisory sold 33,486 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $58.9K.
Vident Investment Advisory first reported a position in SANGAMO THERAPEUTICS INC in Q2 2021 and held it in 7 quarters.
Vident Investment Advisory's SANGAMO THERAPEUTICS INC position peaked at $218K in Q2 2021.
152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.